Adaptive immunity in the liver

Cellular and Molecular Immunology

Volumn 13, Issue 3, 2016, Pages 354-368

  Shuai, Zongwen ^a,b   Leung, Miranda W Y ^a   He, Xiaosong ^a   Zhang, Weici ^a   Yang, Guoxiang ^a   Leung, Patrick S C ^a   Eric Gershwin, M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

adaptive immunity; antiviral immunity; immunopathogenesis; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL SURFACE RECEPTOR; CHEMOKINE; CYTOKINE;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER DISEASE; LYMPHOCYTE FUNCTION; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY; LIVER; PATHOLOGY; T LYMPHOCYTE; VIROLOGY; VIRUS INFECTION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; LIVER; LIVER DISEASES; MODELS, BIOLOGICAL; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 84966356267     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2016.4     Document Type: Review

References (205)

1. Bogdanos DP, Gao B, Gershwin ME. Liver immunology. Compr Physiol 2013; 3: 567-598.
2. Doherty DG. Immunity, tolerance and autoimmunity in the liver: a comprehensive review. J Autoimmun 2015; 66: 60-75.
3. Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M et al. Human liver-resident CD56/CD16 NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun 2015; 66: 40-50.
4. Xu X, Zhang S, Jin R, Wang K, Li P, Lin L et al. Retention and tolerance of autoreactive CD4(+) recent thymic emigrants in the liver. J Autoimmun 2015; 56: 87-97.
5. Zhang H, Liu Y, Bian Z, Huang S, Han X, You Z et al. The critical role of myeloid-derived suppressor cells and FXR activation in immunemediated liver injury. J Autoimmun 2014; 53: 55-66.
6. Selmi C, Podda M, Gershwin ME. Old and rising stars in the lymphoid liver. Semin Immunopathol 2009; 31: 279-282.
7. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61.
8. Sprent J, Surh CD. T cell memory. Annu Rev Immunol 2002; 20: 551-579.
9. Bertolino P, Bowen DG, McCaughan GW, Fazekas de St Groth B. Antigen-specific primary activation of CD8+ T cells within the liver. J Immunol 2001; 166: 5430-5438.
10. Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV. CD40 activation rescues antiviral CD8(+) T cells from PD-1-mediated exhaustion. PLoS Pathog 2013; 9: e1003490.
11. Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010; 10: 753-766.
12. Crispe IN. Liver antigen-presenting cells. J Hepatol 2011; 54: 357-365.
13. Iannacone M, Sitia G, Ruggeri ZM, Guidotti LG. HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol 2007; 46: 719-726.
14. Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L et al. Interleukin-17- producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81-91.
15. Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 2011; 141: 1897-1906.
16. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-747.
17. Shen C, Yan WZ, Zhao CY, Che HH, Liu XY, Liu ZZ et al. Increased CD4+CD25+ regulatory T cells correlate with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients. J Microbiol Immunol Infect 2015; 48: 137-146.
18. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
19. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA 2005; 102: 9913-9917.
20. Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002; 76: 3570-3574.
21. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/ beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000; 74: 4165-4173.
22. Isogawa M, Furuichi Y, Chisari FV. Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity 2005; 23: 53-63.
23. Boettler T, Panther E, Bengsch B, Nazarova N, Spangenberg HC, Blum HE et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 2006; 80: 3532-3540.
24. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225.
25. Chen M, Sallberg M, Hughes J, Jones J, Guidotti LG, Chisari FV et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005; 79: 3016-3027.
26. Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963-973.
27. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-971.
28. Kong X, Sun R, Chen Y, Wei H, Tian Z. gammadeltaT cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance. In J Immunol 2014, 1645-1653.
29. Chen S, Akbar SM, Abe M, Hiasa Y, Onji M. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol 2011; 166: 134-142.
30. Fisicaro P, Valdatta C, Massari M, Loggi E, Ravanetti L, Urbani S et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 2012; 143: 1576-1585.
31. Raziorrouh B, Schraut W, Gerlach T, Nowack D, Gruner NH, Ulsenheimer A et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8 + T-cell function. Hepatology 2010; 52: 1934-1947.
32. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138: 682-693.
33. Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 2014; 61: 1212-1219.
34. Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 2012; 7: e47648.
35. Dolina JS, Braciale TJ, Hahn YS. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box in mice. Hepatology 2014; 59: 1351-1365.
36. Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008; 118: 1835-1845.
37. Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011; 53: 1494-1503.
38. Park SH, Veerapu NS, Shin EC, Biancotto A, McCoy JP, Capone S et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med 2013; 19: 1638-1642.
39. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-662.
40. Smyk-Pearson S, Tester IA, Klarquist J, Palmer BE, Pawlotsky JM, Golden-Mason L et al. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol 2008; 82: 1827-1837.
41. Semmo N, Day CL, Ward SM, Lucas M, Harcourt G, Loughry A et al. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005; 41: 1019-1028.
42. Kared H, Fabre T, Bedard N, Bruneau J, Shoukry NH. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 2013; 9: e1003422.
43. Urbani S, Amadei B, Fisicaro P, Tola D, Orlandini A, Sacchelli L et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006; 44: 126-139.
44. Lucas M, Ulsenheimer A, Pfafferot K, Heeg MH, Gaudieri S, Gruner N et al. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One 2007; 2: e649.
45. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38: 1437-1448.
46. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005; 79: 7860-7867.
47. Hou X, Song J, Su J, Huang D, Gao W, Yan J et al. CD4(+)Foxp3(+) Tregs protect against innate immune cell-mediated fulminant hepatitis in mice. Mol Immunol 2015; 63: 420-427.
48. Shin EC, Park SH, Demino M, Nascimbeni M, Mihalik K, Major M et al. Delayed induction, not impaired recruitment, of specific CD8(+) T cells causes the late onset of acute hepatitis C. Gastroenterology 2011; 141: 686-695.
49. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-1655.
50. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010; 6: e1000947.
51. Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D, Roggendorf M et al. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology 2005; 42: 828-837.
52. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH et al. Impaired effector function of hepatitis C virusspecific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 3447-3458.
53. Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014; 61: 538-543.
54. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A et al. Hepatic expansion of a virus-specific regulatory CD8 (+) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004; 113: 963-972.
55. Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, Nolan BE, Longworth S, Berical A et al. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol 2008; 82: 3154-3160.
56. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81: 2545-2553.
57. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007; 45: 588-601.
58. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 2007; 81: 9249-9258.
59. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM et al. Tim-3 expression on PD-1+ HCVspecific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010; 120: 4546-4557.
60. Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 2009; 83: 9122-9130.
61. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009; 5: e1000313.
62. May S, Ngui SL, Collins S, Lattimore S, Ramsay M, Tedder RS et al. Molecular epidemiology of newly acquired hepatitis C infections in England 2008-2011: genotype, phylogeny and mutation analysis. J Clin Virol 2015; 64: 6-11.
63. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 2015; 24: 1-17.
64. Lin CL, Kao JH. Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol 2013; 28: 10-17.
65. Miroux C, Vausselin T, Delhem N. Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response. Expert Opin Biol Ther 2010; 10: 1563-1572.
66. Wu H, Chen P, Liao R, Li YW, Yi Y, Wang JX et al. Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients. J Gastroenterol Hepatol 2013; 28: 1555-1564.
67. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45: 246-253.
68. Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M et al. Comprehensive analysis of the alpha-fetoproteinspecific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology 2008; 48: 1821-1833.
69. Harimoto H, Shimizu M, Nakagawa Y, Nakatsuka K, Wakabayashi A, Sakamoto C et al. Inactivation of tumor-specific CD8(+) CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol 2013; 91: 545-555.
70. Carulli L, Anzivino C. Telomere and telomerase in chronic liver disease and hepatocarcinoma. World J Gastroenterol 2014; 20: 6287-6292.
71. Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 2010; 16: 2518-2528.
72. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 2689-2697.
73. Xu H, Gu N, Liu ZB, Zheng M, Xiong F, Wang SY et al. NY-ESO-1 expression in hepatocellular carcinoma: a potential new marker for early recurrence after surgery. Oncol Lett 2012; 3: 39-44.
74. Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 2005; 174: 1709-1716.
75. Yang ZQ, Yang ZY, Zhang LD, Ping B, Wang SG, Ma KS et al. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients. Hum Immunol 2010; 71: 1180-1186.
76. Alisa A, Ives A, Pathan AA, Navarrete CV, Williams R, Bertoletti A et al. Analysis of CD4+ T-Cell responses to a novel alpha-fetoproteinderived epitope in hepatocellular carcinoma patients. Clin Cancer Res 2005; 11: 6686-6694.
77. Witkowski M, Spangenberg HC, Neumann-Haefelin C, Buttner N, Breous E, Kersting N et al. Lack of ex vivo peripheral and intrahepatic alpha-fetoprotein-specific CD4+ responses in hepatocellular carcinoma. Int J Cancer 2011; 129: 2171-2182.
78. Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res 2013; 73: 2435-2444.
79. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902-911.
80. Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 2005; 41: 722-730.
81. Greten TF, Ormandy LA, Fikuart A, Hochst B, Henschen S, Horning M et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010; 33: 211-218.
82. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 2007; 7: 804-813.
83. Shen Y, Wei Y, Wang Z, Jing Y, He H, Yuan J et al. TGF-beta regulates hepatocellular carcinoma progression by inducing Treg cell polarization. Cell Physiol Biochem 2015; 35: 1623-1632.
84. Shen P, Wang A, He M, Wang Q, Zheng S. Increased circulating Lin (-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res 2014; 44: 639-650.
85. Schrader J. The role of MDSCs in hepatocellular carcinoma-in vivo veritas? J Hepatol 2013; 59: 921-923.
86. Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol 2011, 156-164.
87. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009, 799-807.
88. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-243.
89. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine- 2, 3-dioxygenase production in hepatocellular carcinoma. Hepatology 2014; 59: 567-579.
90. Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M, Xing MY et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011; 17: 3322-3329.
91. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011; 128: 887-896.
92. Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2009; 137: 682-690.
93. Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One 2011; 6: e23621.
94. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15: 971-979.
95. Umemoto Y, Okano S, Matsumoto Y, Nakagawara H, Matono R, Yoshiya S et al. Prognostic impact of programmed cell death 1 ligand expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol 2015; 50: 65-75.
96. Fujiwara K, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Uemura M et al. Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19: 1121-1127.
97. Rigopoulou EI, Bogdanos DP. Is primary biliary cirrhosis rare or common? The truth lies somewhere in between. Liver Int 2014; 34: e165-e167.
98. Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis 2014; 34: 318-328.
99. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Hepatology 2015; 62: 1620-1622.
100. Wang L, Wang FS, Chang C, Gershwin ME. Breach of tolerance: primary biliary cirrhosis. Semin Liver Dis 2014; 34: 297-317.
101. Chang CH, Chen YC, Yu YH, Tao MH, Leung PS, Ansari AA et al. Innate immunity drives xenobiotic-induced murine autoimmune cholangitis. Clin Exp Immunol 2014; 177: 373-380.
102. Chang CH, Chen YC, Zhang W, Leung PS, Gershwin ME, Chuang YH. Innate immunity drives the initiation of a murine model of primary biliary cirrhosis. PloS One 2015; 10: e0121320.
103. Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat Commun 2015; 6: 8019.
104. Dong M, Li J, Tang R, Zhu P, Qiu F, Wang C et al. Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population. Clin Rev Allergy Immunol 2015; 48: 316-321.
105. Kurth MJ, Yokoi T, Gershwin ME. Halothane-induced hepatitis: paradigm or paradox for drug-induced liver injury. Hepatology 2014; 60: 1473-1475.
106. Lleo A, Zhang W, Zhao M, Tan Y, Bernuzzi F, Zhu B et al. DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. Clin Epigenetics 2015; 7: 61.
107. Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J et al. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int 2015; 35: 642-651.
108. Tana MM, Shums Z, Milo J, Norman GL, Leung PS, Gershwin ME et al. The significance of autoantibody changes over time in primary biliary cirrhosis. Am J Clin Pathol 2015; 144: 601-606.
109. Tomiyama T, Yang GX, Zhao M, Zhang W, Tanaka H, Wang J et al. The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. Cell MolI Immunol 2015; e-pub ahead of print 21 September 2015; doi:10. 1038/cmi. 2015. 86.
110. Wang J, Yang GX, Tsuneyama K, Gershwin ME, Ridgway WM, Leung PS. Animal models of primary biliary cirrhosis. Semin Liver Dis 2014; 34: 285-296.
111. Li Y, Wang W, Tang L, He X, Yan X, Zhang X et al. Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis. Hepatology 2015; 61: 1998-2007.
112. Lleo A, Zhang W, McDonald WH, Seeley EH, Leung PS, Coppel RL et al. Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology 2014; 60: 1314-1323.
113. Zhang J, Zhang W, Leung PS, Bowlus CL, Dhaliwal S, Coppel RL et al. Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology 2014; 60: 1708-1716.
114. Lleo A, Bowlus CL, Yang GX, Invernizzi P, Podda M, Van de Water J et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 2010; 52: 987-998.
115. Rong G, Zhong R, Lleo A, Leung PS, Bowlus CL, Yang GX et al. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology 2011; 54: 196-203.
116. Kita H, Lian ZX, Van de Water J, He XS, Matsumura S, Kaplan M et al. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 2002; 195: 113-123.
117. Colucci G, Schaffner F, Paronetto F. In situ characterization of the cell-surface antigens of the mononuclear cell infiltrate and bile duct epithelium in primary biliary cirrhosis. Clin Immunol Immunopathol 1986; 41: 35-42.
118. Kita H, Matsumura S, He XS, Ansari AA, Lian ZX, Van de Water J et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002; 109: 1231-1240.
119. Wakabayashi K, Yoshida K, Leung PS, Moritoki Y, Yang GX, Tsuneyama K et al. Induction of autoimmune cholangitis in nonobese diabetic (NOD). 1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol 2009; 155: 577-586.
120. Wakabayashi K, Lian ZX, Leung PS, Moritoki Y, Tsuneyama K, Kurth MJ et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 2008; 48: 531-540.
121. Ambrosini YM, Yang GX, Zhang W, Tsuda M, Shu S, Tsuneyama K et al. The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin Exp Immunol 2011; 166: 110-120.
122. Yang GX, Lian ZX, Chuang YH, Moritoki Y, Lan RY, Wakabayashi K et al. Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology 2008; 47: 1974-1982.
123. Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I et al. Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008; 134: 1482-1493.
124. Yao Y, Yang W, Yang YQ, Ma HD, Lu FT, Li L et al. Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Ralpha mice. Journal of autoimmunity 2014; 51: 99-108.
125. Hsu W, Zhang W, Tsuneyama K, Moritoki Y, Ridgway WM, Ansari AA et al. Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha mice. Hepatology 2009; 49: 133-140.
126. Kawata K, Yang GX, Ando Y, Tanaka H, Zhang W, Kobayashi Y et al. Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFbetaRII mice. Hepatology 2013; 58: 1094-1104.
127. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995; 181: 1835-1845.
128. Van de Water J, Ansari A, Prindiville T, Coppel RL, Ricalton N, Kotzin BL et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med 1995; 181: 723-733.
129. Shimoda S, Miyakawa H, Nakamura M, Ishibashi H, Kikuchi K, Kita H et al. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J Autoimmun 2008; 31: 110-115.
130. Lan RY, Salunga TL, Tsuneyama K, Lian ZX, Yang GX, Hsu W et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009; 32: 43-51.
131. Yang CY, Ma X, Tsuneyama K, Huang S, Takahashi T, Chalasani NP et al. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology 2014; 59: 1944-1953.
132. Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, Moritoki Y et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006; 43: 729-737.
133. Aoki CA, Roifman CM, Lian ZX, Bowlus CL, Norman GL, Shoenfeld Y et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 2006; 27: 50-53.
134. Tanaka H, Zhang W, Yang GX, Ando Y, Tomiyama T, Tsuneyama K et al. Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells. Clin Exp Immunol 2014; 178: 253-261.
135. Huang W, Kachapati K, Adams D, Wu Y, Leung PS, Yang GX et al. Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1 (+) CD8 effector cells and defective T regulatory cells. J Autoimmun 2014; 50: 123-134.
136. Wang YH, Yang W, Yang JB, Jia YJ, Tang W, Gershwin ME et al. Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis. J Autoimmun 2015; 59: 26-37.
137. Yang JB, Wang YH, Yang W, Lu FT, Ma HD, Zhao ZB et al. Successful treatment of murine autoimmune cholangitis by parabiosis: Implications for hematopoietic therapy. J Autoimmun 2015; 66: 108-117.
138. Wang L, Sun X, Qiu J, Cai Y, Ma L, Zhao P et al. Increased numbers of circulating ICOS(+) follicular helper T and CD38(+) plasma cells in patients with newly diagnosed primary biliary cirrhosis. Dig Dis Sci 2015; 60: 405-413.
139. Wang L, Sun Y, Zhang Z, Jia Y, Zou Z, Ding J et al. CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology 2015; 61: 627-638.
140. Chuang YH, Lan RY, Gershwin ME. The immunopathology of human biliary cell epithelium. Semin Immunopathol 2009; 31: 323-331.
141. Shimoda S, Harada K, Niiro H, Taketomi A, Maehara Y, Tsuneyama K et al. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology 2010; 51: 567-575.
142. Alabraba EB, Lai V, Boon L, Wigmore SJ, Adams DH, Afford SC. Coculture of human liver macrophages and cholangiocytes leads to CD40-dependent apoptosis and cytokine secretion. Hepatology 2008; 47: 552-562.
143. Lleo A, Shimoda S, Ishibashi H, Gershwin ME. Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes. J Gastroenterol 2011; 46 (Suppl 1): 29-38
144. Lleo A, Liao J, Invernizzi P, Zhao M, Bernuzzi F, Ma L et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 2012; 55: 153-160.
145. Tanaka H, Yang GX, Iwakoshi N, Knechtle SJ, Kawata K, Tsuneyama K et al. Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clin Exp Immunol 2013; 174: 364-371.
146. Dhirapong A, Yang GX, Nadler S, Zhang W, Tsuneyama K, Leung P et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 2013; 57: 708-715.
147. Floreani A, Franceschet I, Cazzagon N, Spinazze A, Buja A, Furlan P et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol 2015; 48: 192-197.
148. Floreani A, Motta R, Cazzagon N, Franceschet I, Roncalli M, Del Ross T et al. The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. Dig Liver Dis 2015; 47: 432-435
149. Floreani A, Spinazze A, Caballeria L, Reig A, Cazzagon N, Franceschet I et al. Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers. Clin Rev Allergy Immunol 2015; 48: 254-262.
150. Rong G, Wang H, Bowlus CL, Wang C, Lu Y, Zeng Z et al. Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. Clin Rev Allergy Immunol 2015; 48: 132-141.
151. Huang X, Wu H, Lu Q. The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol 2014; 47: 219-233.
152. Seldin MF. The genetics of human autoimmune disease: a perspective on progress in the field and future directions. J Autoimmun 2015; 64: 1-12.
153. Webb GJ, Hirschfield GM. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun 2015; 66: 25-39.
154. Webb GJ, Siminovitch KA, Hirschfield GM. The immunogenetics of primary biliary cirrhosis: a comprehensive review. J Autoimmun 2015; 64: 42-52.
155. Beuers U, Gershwin ME. Unmet challenges in immune-mediated hepatobiliary diseases. Clin Rev Allergy Immunol 2015; 48: 127-131.
156. Czaja AJ. Diagnosis and management of autoimmune hepatitis. Clin Liver Dis 2015; 19: 57-79.
157. Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci 2011; 56: 3421-3438.
158. Cancado EL, Abrantes-Lemos CP, Terrabuio DR. The importance of autoantibody detection in autoimmune hepatitis. Front Immunol 2015; 6: 222.
159. Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun 2013; 41: 126-139.
160. Taubert R, Hardtke-Wolenski M, Noyan F, Wilms A, Baumann AK, Schlue J et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol 2014; 61: 1106-1114.
161. Miao Q, Bian Z, Tang R, Zhang H, Wang Q, Huang S et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin Rev Allergy Immunol 2015; 48: 226-235.
162. Ikeda A, Aoki N, Kido M, Iwamoto S, Nishiura H, Maruoka R et al. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice. Hepatology 2014; 60: 224-236.
163. Aoki N, Kido M, Iwamoto S, Nishiura H, Maruoka R, Tanaka J et al. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. Gastroenterology 2011; 140: 1322-1333.
164. Kido M, Watanabe N, Okazaki T, Akamatsu T, Tanaka J, Saga K et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 2008; 135: 1333-1343.
165. Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006; 176: 4484-4491.
166. Liberal R, Grant CR, Holder BS, Ma Y, Mieli-Vergani G, Vergani D et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology 2012; 56: 677-686.
167. Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One 2011; 6: e18909.
168. Singer BD, King LS, D'Alessio FR. Regulatory T cells as immunotherapy. Front Immunol 2014; 5: 46.
169. Maruoka R, Aoki N, Kido M, Iwamoto S, Nishiura H, Ikeda A et al. Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology 2013; 145: 209-220.
170. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225-1232.
171. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol 2006; 177: 6780-6786.
172. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
173. Grant CR, Liberal R, Holder BS, Cardone J, Ma Y, Robson SC et al. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology 2014; 59: 1007-1015.
174. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004; 41: 31-37.
175. Ferri S, Longhi MS, De Molo C, Lalanne C, Muratori P, Granito A et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010; 52: 999-1007.
176. Peiseler M, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 2012; 57: 125-132.
177. Muratori L, Longhi MS. The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies. J Autoimmun 2013; 46: 74-80.
178. Hammerich L, Tacke F. Role of gamma-delta T cells in liver inflammation and fibrosis. World J Gastrointest Pathophysiol 2014; 5: 107-113.
179. Liu X, Jiang X, Liu R, Wang L, Qian T, Zheng Y et al. B cells expressing CD11b effectively inhibit CD4+ T-cell responses and ameliorate experimental autoimmune hepatitis in mice. Hepatology 2015; 62: 1563-1575.
180. Bai L, Zhang W, Tan L, Yang H, Ge M, Zhu C et al. Hepatitis B virus hijacks CTHRC1 to evade host immunity and maintain replication. J. Mol Cell Biol 2015; 7: 543-556.
181. Yang DR, Zhu HZ. Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war? World J Gastroenterol 2015; 21: 3786-3800.
182. Holz L, Rehermann B. T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antiviral Res 2015; 114: 96-105.
183. Montano-Loza AJ, Czaja AJ. Cell mediators of autoimmune hepatitis and their therapeutic implications. Dig Dis Sci 2015; 60: 1528-1542.
184. Isogawa M, Tanaka Y. Immunobiology of hepatitis B virus infection. Hepatol Res 2015; 45: 179-189.
185. Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis- Update 2015. J Hepatol 2015; 62: S100-S111.
186. Dardalhon V, Korn T, Kuchroo VK, Anderson AC. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008; 31: 252-256.
187. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
188. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigenspecific proliferation and cytokine production. J Immunol 1993; 150: 353-360.
189. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
190. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
191. Suh WK. Life of T follicular helper cells. Mol Cells 2015; 38: 195-201.
192. Webb GJ, Hirschfield GM. Follicles, germinal centers, and immune mechanisms in primary biliary cirrhosis. Hepatology 2015; 61: 424-427.
193. Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O'Farrelly C et al. CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009; 183: 7602-7610.
194. Sebastiani S, Allavena P, Albanesi C, Nasorri F, Bianchi G, Traidl C et al. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. In J Immunol 2001, 996-1002.
195. Mittrucker HW, Visekruna A, Huber M. Heterogeneity in the differentiation and function of CD8(+) T cells. Arch Immunol Ther Exp (Warsz) 2014; 62: 449-458.
196. Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 2009; 114: 596-599.
197. Sinha S, Itani FR, Karandikar NJ. Immune regulation of multiple sclerosis by CD8+ T cells. Immunol Res 2014; 59: 254-265.
198. Boer MC, van Meijgaarden KE, Joosten SA, Ottenhoff TH. CD8+ regulatory T cells, and not CD4+ T cells, dominate suppressive phenotype and function after in vitro live Mycobacterium bovis-BCG activation of human cells. PLoS One 2014; 9: e94192.
199. Wu Y, Wu W, Wong WM, Ward E, Thrasher AJ, Goldblatt D et al. Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol 2009; 183: 5622-5629.
200. Kenna T, Golden-Mason L, Norris S, Hegarty JE, O'Farrelly C, Doherty DG. Distinct subpopulations of gamma delta T cells are present in normal and tumor-bearing human liver. Clin Immunol 2004; 113: 56-63.
201. Hoh A, Dewerth A, Vogt F, Wenz J, Baeuerle PA, Warmann SW et al. The activity of gammadelta T cells against paediatric liver tumour cells and spheroids in cell culture. Liver Int 2013; 33: 127-136.
202. Ajuebor MN, Jin Y, Gremillion GL, Strieter RM, Chen Q, Adegboyega PA. GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk. J Virol 2008; 82: 9564-9576.
203. Lu Y, Wang X, Yan W, Wang H, Wang M, Wu D et al. Liver TCRgammadelta(+) CD3(+) CD4(-) CD8(-) T cells contribute to murine hepatitis virus strain 3-induced hepatic injury through a TNF-alpha-dependent pathway. Mol Immunol 2012; 52: 229-236.
204. Rhodes KA, Andrew EM, Newton DJ, Tramonti D, Carding SR. A subset of IL-10-producing gammadelta T cells protect the liver from Listeria-elicited, CD8(+) T cell-mediated injury. Eur J Immunol 2008; 38: 2274-2283.
205. Hammerich L, Bangen JM, Govaere O, Zimmermann HW, Gassler N, Huss S et al. Chemokine receptor CCR6-dependent accumulation of gammadelta T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 2014; 59: 630-642.